Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors

– Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s ImmTOR™...
November 12, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference

WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
November 11, 2019 09:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout

– Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies – –...
November 08, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic...
November 01, 2019 08:09 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call

WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
October 24, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting

WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
October 23, 2019 10:48 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress

Highlights the ability to prevent formation of vector-induced neutralizing antibodies (Nabs) and enable re-administration of AAV vectors in combination with Selecta’s ImmTOR (SVP-Rapamycin)...
September 25, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Two Investor Conferences in October

WATERTOWN, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 04, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer

WATERTOWN, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 03, 2019 08:07 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Janney Healthcare Conference

WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...